Navigation Links
Sun Pharma Commences All Cash Tender Offer to Purchase Taro Ordinary Shares for USD 7.75 Per Share
Date:6/30/2008

MUMBAI, India, June 30 /PRNewswire-FirstCall/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) today announced that Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), a subsidiary of Sun Pharma, has commenced a tender offer for all outstanding Ordinary Shares of Taro Pharmaceutical Industries Ltd. (Taro) for USD 7.75 per share in cash.

On May 18, 2007, Taro and Sun Pharma's subsidiaries entered into a Merger Agreement whereby Sun Pharma's subsidiary would acquire Taro, which the Taro Board of Directors unanimously approved. In the event the merger was not consummated, Taro's controlling shareholders led by Taro's Chairman, Barrie Levitt, granted Sun Pharma an option to acquire all their shares, including all of the Founders' Shares of Taro. On May 28, 2008, Taro improperly terminated the Merger Agreement, an action which Sun has challenged in the Supreme Court of the State of New York.

On June 25, 2008, Alkaloida exercised its Option under its Option Agreement to acquire all the shares held by the controlling shareholders of Taro. As required by the Option Agreement, Alkaloida has commenced a Tender Offer for all Ordinary Shares. The Option Agreement required that the Tender Offer be at USD 7.75 per share.

The tender offer is scheduled to expire at 12:00 midnight, New York City time, on Monday, July 28, 2008, unless the tender offer is extended.

The tender offer is not conditioned on the availability of financing or the approval of the Board of Directors of Taro.

The complete terms and conditions will be set out in the Offer to Purchase, which will be filed with the U.S. Securities and Exchange Commission today, June 30, 2008. Taro shareholders may obtain copies of all of the offering documents, including the Offer to Purchase, free of charge at the SEC's website (http://www.sec.gov) or by directing a request to MacKenzie Partners, Inc., the Information Agent for the offer, at 105 Madison Avenue, New York, New York 10016, (212) 929-5500 (Call Collect) or Call Toll-Free (800) 322-2885, Email: tenderoffer@mackenziepartners.com.

Greenhill & Co., LLC is acting as the Dealer Manager for the tender offer and MacKenzie is acting as the Information Agent for the tender offer.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, U.S. and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at http://www.sunpharma.com.

Contacts

Uday Baldota

Tel +91 22 6645 5645, Xtn 605

Tel Direct +91 22 66455605

Mobile +91 98670 10529

E mail uday.baldota@sunpharma.com

Mira Desai

Tel +91 22 6645 5645, Xtn 606

Tel Direct +91 22 66455606

Mobile +91 98219 23797

E mail mira.desai@sunpharma.com

Brunswick Group for Sun Pharma MacKenzie Partners

Nina Devlin / Erin Becker Robert Marese

+1 212 333 3810 +1 212 929 5500

Arad Communications for Sun Pharma Greenhill

Gali Dahan Ashish Contractor

+972 3 7693320 +1 212 389 1537


'/>"/>
SOURCE Sun Pharmaceutical Industries Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The University of Toledo selects SXC Health Solutions (informedRx) to provide pharmacy benefit management services
2. Pharmacy Technician Certification Board (PTCB) Supports Florida's New Patient Safety Solution
3. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
4. MDS Pharma Services Names Dr. Lori McDonald to Executive Leadership Team
5. Avalon Pharmaceuticals names lead development candidate in beta-catenin inhibitor program
6. KV Pharmaceutical Company Completes Fiscal 2008 Filings With Securities and Exchange Commission
7. Fischman receives Pharmacology/Therapeutics/Toxicology Research Award
8. Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index
9. Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards
10. CEVA Logistics Awarded Best 3PL Provider for Pharmaceutical, Chemical, HazMat and Fresh Food Supply Chains
11. NACDS Praises House Legislation to Delay Medicaid Cuts, Aid Pharmacies in Treating Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... Tijuana Bariatrics ... which the practice operates, is now dedicated solely to bariatrics. , This means that ... ever before. The expansion of the fourth floor improves the practice’s ability to treat ...
(Date:5/6/2016)... ... ... associated with Mother’s Day is mixed with worry and fear for new mothers those whose ... For the first time ever, the March of Dimes and Random Acts ... beside a crib surrounded by lifesaving equipment or peering through a glass window at a ...
(Date:5/6/2016)... Jupiter, FL (PRWEB) , ... May 06, 2016 ... ... it will feature AsedaSciences® in an upcoming episode, airing third quarter 2016, via ... with the vision of becoming a leader in optimized drug discovery through innovative ...
(Date:5/6/2016)... ... 06, 2016 , ... From the Speaker Podium to the Exhibit Floor at ... insights on managing Customers Engagement at SpeechTek 2016 Event, taking place May 23-25 at ... a Presentation on “5 Customer Engagement Strategies to improve Customer Satisfaction in ...
(Date:5/6/2016)... ... May 06, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... he has found in the Bible about helping to stop cancer. Yisrayl says there are ... his hope that the health and science industries will pay close attention and take action. ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016 ... the  "Global Actinic Keratosis Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Keratosis epidemiology, Actinic Keratosis market valuations and ...
(Date:5/3/2016)... 3, 2016 BioNovus Innovations LLC and ... Advancing Medical Innovation (IAMI) today announced a new ... and medical devices. An agreement between ... to license, develop and commercialize medical innovations advanced ... "This partnership represents a significant advance in our ...
(Date:5/3/2016)... 3, 2016  As a teenager, an active and ... which damaged his heart. He continued enjoying sports and ... 2013, Shepherd,s heart was giving out and he was ... 20, 2013, the Mesa, Arizona ... Like a heart transplant, the SynCardia TAH-t is the ...
Breaking Medicine Technology: